ClinicalTrials.gg
Active, not recruitingNCT06258057Updated Apr 6, 2026

Safety of Tetanus, Diphtheria, Acellular Pertussis With 5 Acellular Pertussis Components (Tdap5) Vaccination During Pregnancy

An observational study in Pertussis (Whooping Cough), sponsored by Sanofi. Active, not recruiting at 1 site in France. Open to female participants aged 15 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-06.

Sponsored by Sanofi · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
365,000
Ages
15 Years to 49 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 83 studies in Whooping Cough by Sanofi — 1 open to participants now, 2 under way, 1 of them phase 3. Whooping Cough · Sanofi.

Planned enrollment
Largest of 11
365,000 · median 3,214
Started
2024
the only one that year
Observational
11 of 83
none open now
Registered
82nd of 83
by date

Among the 83 studies in Whooping Cough by Sanofi, this one has the largest planned enrollment of the 11 observational ones that give a count, is the only one that started in 2024, is one of 11 observational ones, and was the 82nd registered.

Whooping Cough

291 studies on the registry are indexed under Whooping Cough; 24 are open to participants now.

Browse Whooping Cough studies →

Open to participants now

1 of the 83 studies in Whooping Cough by Sanofi is open now. Recruiting first, the newest first:

Who these studies take

Of the 14 Whooping Cough studies recruiting now, 2 (14%) set no upper age limit and 11 (79%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 15 Years to 49 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 83 studies in Whooping Cough by Sanofi, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety of Adacel vaccine among pregnant individuals exposed to Adacel at any point between the 1st day of the 27th week of gestation up to the end of pregnancy and their offspring (ie, Adacel-exposed cohort), in comparison with pregnant individuals not vaccinated with any Tdap vaccines during pregnancy and their offspring (ie, Tdap-unvaccinated comparator cohort).

The primary objectives are to estimate incidence rates and relative risks for each prespecified pregnancy outcome in Adacel-exposed and Tdap-unvaccinated comparator cohorts and for each prespecified adverse birth outcome in the offspring of both cohorts.

The secondary objectives are to estimate incidence rates and relative risks for each prespecified adverse fetal and neonatal outcome in the offspring of Adacel-exposed and Tdap unvaccinated comparator cohorts and for each prespecified adverse outcome for pregnant individuals in both cohorts.

Read the detailed description

This is a retrospective cohort study utilizing existing EHR data to identify eligible pregnant individuals, with an observation period spanning January 2016 through December 2024. Given this study design, follow-up for all pregnancies with documented deliveries is expected to be complete by December 2025.

The study report is expected to be completed by 31 December 2026.

03

Conditions studied

  • Pertussis (Whooping Cough)

Browse trials for

04

Who can participate

Ages eligible
15 Years to 49 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study population will be comprised of 2 cohorts of pregnant individuals with pregnancy onset from 01 January 2016 through 31 December 2024. Infants born from this study population of pregnant individuals with singleton gestation pregnancies will be eligible for inclusion in this study. Eligible live born infants must be born on 01 October 2025 or prior to this date, to allow adequate follow-up time

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For pregnant individuals:

    • Continuous enrollment, with no more than a 1-month administrative gap from 90 days prior to their last menstrual period (LMP)
    • Continuous enrollment for the duration of their pregnancy through delivery or termination of pregnancy (or 6 weeks postpartum for preeclampsia/eclampsia and 28 days for PPH) unless censored at death in order to capture study outcomes
    • At least 1 prenatal visit prior to 27 weeks of gestation during pregnancy
  • For offspring:

    • Infants delivered by pregnant individuals who meet all the inclusion criteria above
    • With gestational age as calculated based on date of birth recorded in the EMR

Exclusion criteria

Exclusion Criteria:

  • For pregnant individuals:

    • Loss of pregnancy or with delivery before 27 weeks of gestation
    • Vaccinated with Boostrix® (Tdap vaccine, GSK), or with an unknown brand of Tdap vaccine, or Td (tetanus, diphtheria) vaccine during pregnancy
    • Vaccinated with any Tdap vaccine prior to the ACIP recommended optimal timeframe of ≥ 27 0/7 weeks of gestation
    • Received more than one Tdap vaccine during pregnancy
    • Vaccinated with one or more during pregnancy
    • Pregnant individuals with multiple gestation pregnancies (eg, twins, triplets)
  • For offspring:

    • Infants delivered by pregnant individuals who meet any of the exclusion criteria above
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
365,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Adacel-Exposed Cohort

    Cohort will include all pregnant individuals with a record of Adacel vaccination during the third trimester of pregnancy (ie, first day of 27th week of gestation up to the end of pregnancy) and their offspring

    Other: Not applicable / database analysis

  • Tdap-Unvaccinated Comparator Cohort

    Cohort will include all pregnant individuals meeting eligibility criteria and with no record of any Tdap vaccination from pregnancy onset date until the end of pregnancy and their offspring

    Other: Not applicable / database analysis

Interventions

  • OtherNot applicable / database analysis

    Not applicable / database analysis

06

What researchers measure

Primary outcomes

  1. Pregnancy outcome: Live birth

    Incidence rates of live births in Adacel-exposed and Tdap-unvaccinated comparator cohorts

    Time frame: From 1st day of the 27th week of gestation up to 42 weeks gestation

  2. Pregnancy outcome: Still birth/fetal demise

    Incidence rates of still birth/fetal demise in Adacel-exposed and Tdap-unvaccinated comparator cohorts

    Time frame: From 1st day of the 27th week of gestation up to 42 weeks gestation

  3. Pregnancy outcome: Therapeutic abortion

    Incidence rates of therapeutic abortion in Adacel-exposed and Tdap-unvaccinated comparator cohorts

    Time frame: From 1st day of the 27th week of gestation up to 42 weeks gestation

  4. Birth outcome: Preterm birth

    Incidence rates of preterm birth in live born infants of both Adacel-exposed and Tdap-unvaccinated comparator cohorts

    Time frame: From 1st day of the 27th week of gestation and less than 37 weeks gestation

  5. Birth outcome: Low birth weight

    Incidence rates of low birth weight in live born infants of both Adacel-exposed and Tdap-unvaccinated comparator cohorts

    Time frame: From 1st day of the 27th week of gestation up to 42 weeks gestation

  6. Birth outcome: Small for gestational age

    Incidence rates of small for gestational age in live born infants of both Adacel-exposed and Tdap-unvaccinated comparator cohorts

    Time frame: From 1st day of the 27th week of gestation up to 42 weeks gestation

Secondary outcomes

  1. Adverse neonatal outcome: Neonatal death

    Incidence rates of neonatal death in the offspring of Adacel-exposed and Tdap-unvaccinated comparator cohorts

    Time frame: From birth up to 28 days post-birth

  2. Adverse neonatal outcome: Neonatal sepsis

    Incidence rates of neonatal sepsis in the offspring of Adacel-exposed and Tdap-unvaccinated comparator cohorts

    Time frame: From birth up to 28 days post-birth

  3. Adverse neonatal outcome: Neonatal respiratory distress

    Incidence rates of neonatal respiratory distress in the offspring of Adacel-exposed and Tdap-unvaccinated comparator cohorts

    Time frame: From birth up to 28 days post-birth

  4. Adverse neonatal outcome: Congenital anomalies

    Incidence rates of congenital anomalies (major and minor) in the offspring of Adacel-exposed and Tdap-unvaccinated comparator cohorts

    Time frame: From birth up to 28 days post-birth

  5. Adverse neonatal outcome: Neonatal/early infancy intensive care admissions for bronchopulmonary dysplasia

    Incidence rates of neonatal/early infancy intensive care admissions for bronchopulmonary dysplasia in the offspring of Adacel-exposed and Tdap-unvaccinated comparator cohorts

    Time frame: From birth up to 28 days post-birth

  6. Adverse fetal outcome: Fetal growth arrest (restriction)

    Incidence rates of fetal growth arrest (restriction) in Adacel-exposed and Tdap-unvaccinated comparator cohorts

    Time frame: From 1st day of the 27th week of gestation up to 42 weeks gestation

  7. Adverse outcomes in pregnant individuals: Preterm labor

    Incidence rates of Preterm labor in Adacel-exposed and Tdap-unvaccinated comparator cohorts

    Time frame: From 1st day of the 27th week of gestation and less than 37 weeks gestation

  8. Adverse outcomes in pregnant individuals: Preeclampsia/eclampsia

    Incidence rates of preeclampsia/eclampsia in Adacel-exposed and Tdap-unvaccinated comparator cohorts

    Time frame: From 1st day of the 27th week of gestation up to 42 days postpartum

  9. Adverse outcomes in pregnant individuals: Postpartum hemorrhage

    Incidence rates of postpartum hemorrhage in Adacel-exposed and Tdap-unvaccinated comparator cohorts

    Time frame: Within 24 hours of delivery up to 28 days postpartum

  10. Adverse outcomes in pregnant individuals: Placental abruption

    Incidence rates of placental abruption in Adacel-exposed and Tdap-unvaccinated comparator cohorts

    Time frame: From 1st day of the 27th week of gestation up to 42 weeks gestation

  11. Adverse outcomes in pregnant individuals: Premature rupture of membranes

    Incidence rates of premature rupture of membranes in Adacel-exposed and Tdap-unvaccinated comparator cohorts

    Time frame: From 1st day of the 27th week of gestation up to 42 weeks gestation

  12. Adverse outcomes in pregnant individuals: Chorioamnionitis

    Incidence rates of chorioamnionitis in Adacel-exposed and Tdap-unvaccinated comparator cohorts

    Time frame: From 1st day of the 27th week of gestation up to 42 weeks gestation

07

Study locations

1 site
  • Investigational Site
    Chilly-Mazarin, 91380, France
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.

Of 22 observational studies under Whooping Cough, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 61. This study's planned 35 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2024
First posted
Feb 14, 2024
StartActual
Jan 2, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06258057
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Feb 14, 2024
Start date
Jan 2, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 6, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion